Wolfe Research analyst Mike Polark initiates coverage on Medtronic (NYSE:MDT) with a Underperform rating.
‘EV Winter’ Is Starting To Take A Toll On Rivian: Analyst Says 2024 Targets Are In Jeopardy
Barclays analyst Dan Levy downgrades Rivian, says "even great product and tech is not enough to avoid the EV winter."